Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease. [PDF]
PLoS One, 2019 Background Serum amyloid A (SAA), a potent inflammatory mediator, and Janus kinase 2 (JAK2), an intracellular signaling kinase, are increased by diabetes. The aims were to elucidate: 1) a JAK2-mediated pathway for increased SAA in the kidneys of diabetic
Dieter BP +9 more
europepmc +2 more sources
Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors. [PDF]
Molecules, 2019 Janus kinase 2 (JAK2) inhibitors represent a promising therapeutic class of anticancer agents against many myeloproliferative disorders. Bioactivity data on pIC50 of 2229 JAK2 inhibitors were employed in the construction of quantitative structure ...
Simeon S, Jongkon N.
europepmc +2 more sources
Frontiers in Medicine, 2023 Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (SLE), conferring immune-mediated properties in target tissues.
Dionysis Nikolopoulos +4 more
doaj +3 more sources
Janus kinase 2 negative polycythemia vera [PDF]
Asian Biomedicine, 2017 Background A Janus kinase 2 (JAK2) mutation polycythemia vera (PV) is a common manifestation of stem cell disorder. However, available data on the clinical and treatment response of JAK2-negative PV patients are limited. Objectives We report the case and
Pravinwan Thungthong +4 more
semanticscholar +2 more sources
Frontiers in Microbiology, 2021 Coronavirus disease 2019 (COVID-19) has caused a crisis to global public health since its outbreak at the end of 2019. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of COVID-19, appears to efficiently evade the host immune ...
Rong Wang +7 more
doaj +2 more sources
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm [PDF]
South Asian Journal of Cancer, 2017 Context: Alterations in megakaryocyte morphology are the hallmark of myeloproliferative neoplasms (MPNs). These neoplasm are also associated with Janus kinase 2 (JAK2) V617F mutation in nearly 95% patients with polycythemia vera (PV), 40% patients of ...
Shuchi Ghai, Sharada Rai
doaj +3 more sources
Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia. [PDF]
Cureus, 2022 Yıldız J, Batgi H.
europepmc +3 more sources
miR-101 Promotes Breast Cancer Cell Apoptosis by Targeting Janus Kinase 2
Cellular Physiology and Biochemistry, 2014 Aims: microRNA-101 (miR-101) is down-regulated in several cancers. In this study, we explored the effects of dysregulated miR-101 on breast cancer cells and the underlying mechanisms. Methods: miR-101 level was quantified by real-time RT-PCR.
Lu Wang +10 more
doaj +2 more sources
Iraqi Journal of HematologyBACKGROUND: Diagnosis of myeloproliferative neoplasms including polycythemia vera (PV) has been greatly improved following the identification of driver mutations at exon 12 and exon 14 of the Janus Kinase 2 (JAK2) gene. There are limited academic studies
Mushtaq M. Khazeem, Alaa Fadhil Alwan
doaj +2 more sources
Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor [PDF]
Tzu Chi Medical Journal, 2019 Polycythemia vera (PV) is relatively uncommon in early adulthood, and evidence about the prevalence of the Janus kinase 2 (JAK2) V617F mutation in the general population is limited.
Shang-Hsien Yang +3 more
doaj +2 more sources